What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

Marta Waliszewska-Prosół; Doga Vuralli; Paolo Martelletti

doi:10.1186/s10194-023-01698-8

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

J Headache Pain. 2023 Dec 5;24(1):163. doi: 10.1186/s10194-023-01698-8.

Authors

Marta Waliszewska-Prosół^#¹, Doga Vuralli^#², Paolo Martelletti³

Affiliations

¹ Department of Neurology, Wrocław Medical University, Borowska 213 Str, 50-556, Wrocław, Poland. marta.waliszewska@gmail.com.
² Department of Neurology and Algology, Neuroscience and Neurotechnology Center of Excellence (NÖROM), Faculty of Medicine, Neuropsychiatry Center, Gazi University, Ankara, Turkey.
³ School of Health Sciences, UnitelmaSapienza University of Rome, Rome, Italy.

^# Contributed equally.

Abstract

In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.

Keywords: CGRP; Combination; Gepants; Responders; Switching.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists* / pharmacology
Calcitonin Gene-Related Peptide Receptor Antagonists* / therapeutic use
Calcitonin Gene-Related Peptide*
Humans
Receptors, Calcitonin Gene-Related Peptide

Substances

Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide
Receptors, Calcitonin Gene-Related Peptide
Antibodies, Monoclonal